Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-06-07
2005-06-07
Fredman, Jeffrey (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C435S069100, C435S320100, C435S325000, C435S455000, C514S04400A
Reexamination Certificate
active
06902731
ABSTRACT:
Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: WO 92/06180 (1992-04-01), None
patent: WO 93/14188 (1993-07-01), None
patent: WO 93/19768 (1993-10-01), None
patent: WO 93/20221 (1993-10-01), None
patent: WO 94/06922 (1994-03-01), None
patent: WO 94/06923 (1994-03-01), None
patent: WO 9507708 (1995-03-01), None
Shimizu, R.T. et al., “The Smooth Muscle α-Actin Gene Promoter Is Differentially Regulated in Smooth Muscle versus Non-smooth Muscle Cells,”J. Biol. Chem.270(13):7631-7643 (1995).
Fueyo, et al., “Expression of exogenous p16/CDKN2 products growth arrest in a glioma cell line that does not express RB protein,”Proceedings of the American Association for Cancer Research,37:A49 (1996).
Xu, et al., “Enhanced Tumor Suppressor Gene Therapy via eplication-deficient Adenivirus Vectors Expressing an N-Terminal Truncated Retinoblastoma Protein,”Cancer Research,56:2245-2249 (1996).
Wills, et al., Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer, Human Gene Therapy (Sep. 1994), pp. 1079-1088, vol. 5, Mary Ann Liebert, Inc. Publishers.
Schuler, et al., A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer, Human Gene Therapy (Sep. 1998), pp. 2075-2082, Mary Ann Liebert, Inc. Publishers.
Nielsen, et al., Combination Therapy with the Famesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models, Cancer Research (Dec. 1, 1999), pp. 5896-5901, vol. 59.
Nielsen, et al., p53 Tumor Suppressor Gene Therapy for Cancer, Cancer Gene Therapy (1998), pp. 52-63, vol. 5, No. 1.
Reid, et al., Intravascular Adenoviral Agents in Cancer Patients: Lessons From Clinical Trials, Cancer Gene Therapy (2002), pp. 980-986, Nature Publishing Group.
Wills, et al., Tissue-Specific Expression of an Anti-Proliferative Hybrid Transgene from the Human Smooth Muscle α-actin Promoter Suppresses Smooth Muscle Cell Proliferation and Neointima Formation, Gene Therapy (2001), pp. 1847-1854, Nature Publishing Group.
Adams, P.D. et al., “Transcriptional control by E2F,”Cancer Biology6:99-108 (1995).
Adnane, J. et al., “The Retinoblastoma Susceptibility Gene Product Represses Transcription When Directly Bound to the Promoter,”J. Biol. Chem.270(15):8837-8843 (1995).
Antelman, D. et al., “Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein,”Oncogene10:697-704 (1995).
Arteaga, C.L. et al., “Tissue-targeted Antisense c-fos Retroviral Vector Inhibits Established Breast Cancer Xenografts in Nude Mice,”Cancer Research56:1098-1103 (1996).
Babajko, S. et al., “Interplay of the Liver-Enriched Transacting Factors, DBP and HNF1, in the Transactivation of Human IGFBP-1 Promoter,”Biochem.&Biophys. Research Commun.196(1):480-486 (1993).
Banas, B. et al., “Analysis of the promoter of the human prostatic acid phosphatase gene,”Biochim. Biophys. Acta1217:188-194 (1994).
Beijersbergen, R.L. et al., “E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo,”Genes&Devel.8:2680-2690 (1994).
Bingle, C.D. et al., “Interaction of CCAAT/enhancer-binding protein α and β with the rat caeruloplasmin gene promoter,”Biochem. J.294:473-479 (1993).
Bookstein, R. et al., “Suppression of Tumorigenicity of Human Prostate Carcinoma Cells by Replacing a Mutated RB Gene,”Science274:712-715 (1990).
Buck, V. et al., “Molecular and functional characterisation of E2F-5, a new member of the E2F family,”Oncogene11:31-38 (1995).
Chang, M.W. et al., “Cystostatic Gene Therapy for Vascular Proliferative Disorders with a Constitutively Active Form of the Retinoblastoma Gene Product,”Science267:518-522 (1995).
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury,”Lab. Invest.49(3) 327 333 (1983).
Cox, G.A. et al., “Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity,”Nature364:725-729 (1993).
Curiel, D.T. et al ., “Adenovirus enhancement of transferrin-polylysine-mediated gene delivery,”Proc. Natl. Acad. Sci. U.S.A.88:8850-8854 (1991).
Dalesandro, J. et al., “Gene Therapy for Donor Hearts: Ex vivo Liposome-Mediated Transfection,”J. Thoracic and Cardiovascular Surgery111(2): 416-422 (1996).
Dobrowolski, S.F. et al., “An E2F dominant negative mutant blocks E1A induced cell cycle progression,”Oncogene9:2605-2612 (1994).
Dowdy, S.F. et al., “Physical Interaction of the Retinoblastoma Protein with Human D Cyclins,”Cell73:499-511 (1993).
Dusetti, N.J. et al., “Structural Organization of the Gene Encoding the Rat Pancreatitis-associated Protein,”J. Biol. Chem.268(19):14470-14475 (1993).
Eisenberger, C.L. et al., “Differential Regulation of the Rat Phosphoenolpyruvate Carboxykinase Gene Expression in Several Tissues of Transgene Mice,”Mol. Cell Biol.12(3):1396-1403 (1992).
Fontaine, R.N. et al., “Structure of the Rat Pancreatic Cholesterol Esterase Gene,”Biochemistry30:7008-7014 (1991).
Forss-Petter, S. et al., “Transgenic Mice Expressing β-Galactosidase in Mature Neurons under Neuron-Specific Enolase Promoter Control,”Neuron5:187-197 (1990).
French, B.A. et al., “Percutaneous Transluminal In Vivo Gene Transfer by Recombinant Adenovirus in Normal Porcine Coronary Arteries, Atherosclerotic Arteries, and Two Models of Coronary Restenosis,”Circulation,90(5):2402-2413 (1994).
Friedman, .M. et al., “Cellular Promoters Incorporated into the Adenovirus Genome: Cell Specificity of Albumin and Immunoglobulin Expression,”Mol. Cell. Biol.6(11):3791-3797 (1986).
Ginsberg, D. et al., “E2F-4, a new member of the E2F transcription factor family, interacts with p107,”Genes&Devel.8:2665-2679 (1994).
Gorman, C.M. et al., “Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells,”Mol. Cell. Biol.2(9):1044-1051 (1982).
Hanson, R.D. et al., “The 5′-Flanking Region of the Human CGL-1/Granzyme B Gene Targets Expression of a REporter Gene to Activated T-lymphocytes in Transgenic Mice,”J. Biol. Chem.266(36):24433-24438 (1991).
Hatzoglou, M. et al., “Hepatic Gene Transfer in Animals Using REtroviruses Containing the Promoter from the Gene for Phosphoenolypyruvate Carboxykinase,”J. Biol. Chem.265(28):17285-17293 (1990).
Helftenbein, G. et al., “Expression of the Uteroglobin Promoter in Epithelial Cell Lines from Endometrium,”Annals New York Acad. Sci.Bulletti C. et al., eds., New York Academy of Sciences, New York, 622:69-79 (1991).
Hemstrom, C. et al., “Gene Product of Region E4 of Adenovirus Type 5 Modulates Accumulation of Certain Viral Polypeptides,”J. Virol.62(9):3258-3264 (1988).
Hiebert, S.W., “Regions of the Retinoblastoma Gene product Required for Its Interaction with the E2F Transcription Factor Are Necessary for E2 Promoter Repression and pRb-Mediated Growth Suppression,”Mol. Cell Biol.13(6):3384-3391 (1993).
Houchins, J.P. et al., “Genomic structure of nkg5, a human NK and T cell-specific activation gene,”Immunogenetics37:102-107 (1993).
Houglum, K. et al., “LAP (NF-IL6) Transactivates the Collagen α1Gene from a 5′ Regulatory Region,”J. Clin. Invest.94:808-814 (1994).
Huang, S. et al., “A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma
Antelman Douglas
Gregory Richard J.
Wills Kenneth N.
Canji Inc.
Fredman Jeffrey
Kaushal Sumesh
LandOfFree
Methods of treating hyperproliferative disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating hyperproliferative disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating hyperproliferative disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512037